Rezafungin is an echinocandin antifungal indicated in patients over 18 years old who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Unlike other echinocandins such as caspofungin and micafungin, rezafungin has long‐acting pharmacokinetics and a high stability that allows for it to have long dosing intervals maintaining high plasma exposure.
- Mechanism
- Curator reviewed · 1 reference
Rezafungin is an echinocandin antifungal drug. It inhibits the 1,3-β-D-glucan synthase enzyme complex present in the cell walls of fungi, responsible for the formation of 1,3-β-D-glucan. Since 1,3-β-D-glucan is an essential component of fungal cell walls, rezafungin disrupts the cell wall of fungal species, including Candida spp., and acts as a concentration-dependent in vitro fungicidal. Mammalian cells do not express β-1-3-glucan synthase; therefore, the action of rezafungin is specific to fungi.
- Primary indication
- Rezafungin is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.Curator reviewed · 2 structured indications
- Formula / weight
- C63H85N8O17 · 1226.411 g/mol (avg)
- First approval
- United States, 2023 · European Union, 2024
- Also known as
- Biafungin · Rezafungin cation · Rezafungin ion
- Code names
- CD-101 · SP-3025
- Brand names
Resolves to
LNFCWEXGZIEGJW-TXSVMFMRSA-OSMILES[H][C@](C)(O)[C@]1([H])\N=C(O)/[C@]([H])(C[C@@]([H])(O)[C@@]([H])(OCC[N+](C)(C)C)\N=C(O)/[C@@]2([H])N(C[C@]([H])(C)[C@]2([H])O)C(=O)[C@@]([H])(\N=C(O)/[C@@]([H])(\N=C(O)/[C@]2([H])C[C@@]([H])(O)CN2C1=O)[C@]([H])(O)[C@@]([H])(O)C1=CC=C(O)C=C1)[C@@]([H])(C)O)\N=C(/O)C1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(OCCCCC)C=C1What you can answer from here — as of September 12, 2026
Which drugs share a target with Rezafungin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account